Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has eight programs in various stages of research and development, with six in clinical development. Its lead program is elagolix for the treatment of endometriosis. The company has not yet generated revenue from product sales and relies on collaborations and equity financing.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenues | $0.8 million | $0.7 million |
| Net Loss | $(8.6) million | $(19.7) million |
| Loss Per Share (Basic & Diluted) | $(0.19) | $(0.51) |
| Operating Expenses | $10.9 million | $19.9 million |
| Cash and Cash Equivalents (End of Period) | $52.2 million | $51.7 million |
| Total Investments | $17.0 million | $22.5 million |
| Net Cash Used in Operating Activities | $(12.2) million | $(14.4) million |
| Net Cash Provided by Financing Activities | $21.4 million | $0 |
Liquidity: As of March 31, 2010, the company held $52.2 million in cash and cash equivalents and $17.0 million in investments. Total current assets were $68.3 million against total current liabilities of $18.6 million.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $19.7 million in Q1 2009 to $8.6 million in Q1 2010. This improvement was driven by a restructuring program implemented in Q2 2009, ongoing expense management, and a shift in investment income.
- Operating Expenses: Total operating expenses dropped from $19.9 million to $10.9 million.
- R&D Expenses: Decreased from $10.8 million to $7.6 million, primarily due to reduced personnel costs following the 2009 restructuring.
- G&A Expenses: Decreased from $4.2 million to $3.2 million due to restructuring and cost controls.
- Cease-use Expense: Dropped dramatically from $4.8 million to $0.1 million. The prior year included significant lease termination costs related to the company's former headquarters.
- Investment Income: Other income improved from a loss of $0.5 million to income of $1.5 million. This was due to a $1.5 million impairment loss on auction rate securities in Q1 2009 versus a $0.6 million realized gain on the sale of auction rate securities in Q1 2010.
- Capital Raise: In March 2010, the company completed a public offering of approximately 10.5 million shares at $2.20 per share, generating net proceeds of approximately $21.4 million.
Outlook, Risks, and Unusual Items
- Future Losses: Management expects to incur operating losses for the foreseeable future as product candidates advance through clinical development. The company had an accumulated deficit of $762.9 million as of March 31, 2010.
- Liquidity of Investments: A significant portion of the investment portfolio ($16.1 million par value) consists of auction rate securities (ARS) that are currently illiquid due to failed auctions. While these are secured by student loans backed by the federal government, the company may not be able to access these funds without a potential loss of principal until a future auction succeeds or the securities mature (2030-2047). The company intends to sell these securities via an ARS Rights program with UBS starting June 30, 2010.
- Real Estate Obligations: The company sold its headquarters in 2007 and leases it back. Following a lease amendment in September 2009, the company vacated the "Front Building" and paid a $4.0 million release fee. It remains obligated to pay rent differentials for the Front Building through 2019.
- Financing Facility: The company has a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited allowing for up to $75.0 million in equity raises over three years. No shares had been issued under this facility as of March 31, 2010.
- Regulatory Risks: The company faces uncertainty regarding the future development of its product candidate indiplon following an FDA approvable letter in 2007 that required additional studies. Clinical trial failures or delays for other candidates (e.g., elagolix) could significantly harm the business.
Key Facts for Investor Verification
- Cash Runway: Verify if the $69.2 million in cash and investments is sufficient to fund operations for the next 12 months given the continued burn rate and lack of product revenue.
- Auction Rate Securities (ARS): Confirm the status of the illiquid ARS portfolio ($14.6 million carrying value) and the timeline for the UBS ARS Rights exercise period beginning June 30, 2010.
- Restructuring Impact: Assess whether the cost savings from the 2009 restructuring are sustainable or if R&D spending will increase as clinical trials progress.
- Indiplon Status: Monitor updates on the indiplon program, as the company has ceased clinical development pending evaluation of alternatives following FDA requirements.
- Lease Obligations: Review the ongoing cash outflows related to the sale-leaseback transaction, specifically the rent differential payments for the vacated Front Building.